Health Matters
Printing is not available for Health Matters content.
Subscribers can read every article in full at health-matters.io.

Aspen Manufacturing to Drive 2027 Growth After mRNA Loss

Aspen Manufacturing to more than double EBITDA in 2027 as sterile operations, insulin and new production lines replace a lost mRNA deal.
Aspen Manufacturing to Drive 2027 Growth After mRNA Loss
Image | Rushay | Shutterstock/2517348357

This article is for Health Matters subscribers

Subscribers read every article in full, receive the daily briefing and have access to the complete archive.

SubscribeLog in

Not ready to subscribe? Get Health Matters Weekly free: the week’s top healthcare headlines every Friday.

More from Health Matters

12.11.2026

Aspen wins generic semaglutide approval in South Africa and Brazil, with launches planned in coming months. Read what this means for diabetes care.

12.11.2026

Learn why the Diabetes Alliance is launching a framework to track diabetes care commitments as South Africa's 2027 NCD targets rapidly approach.

12.11.2026

Learn why Viatris and Innovata are seeking leave to appeal the ARV tender ruling that set aside their TLD contracts, and what it means for supply.